JAK-INHIBITORS TOFACITINIB AND BARICITINIB IMPROVE PATHOLOGICAL BONE LOSS IN VIVO

Adam S, Simon N, Steffen U, Harre N, Andes F, Mueller D, Culemann S, Andreev D, Hahn M, Scholtysek C, Schett G, Krönke G, Frey S, Hueber A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 110-110

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

Event location: Madrid ES

DOI: 10.1136/annrheumdis-2019-eular.4104

Authors with CRIS profile

Susanne Adam Department of Medicine 3 – Rheumatology and Immunology Ulrike Steffen Department of Medicine 3 – Rheumatology and Immunology Darja Andreev Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Gerhard Krönke Professur für Translationale Immunologie Silke Frey Department of Medicine 3 – Rheumatology and Immunology Axel Hueber Department of Medicine 3 – Rheumatology and Immunology

How to cite

APA:

Adam, S., Simon, N., Steffen, U., Harre, N., Andes, F., Mueller, D.,... Hueber, A. (2019). JAK-INHIBITORS TOFACITINIB AND BARICITINIB IMPROVE PATHOLOGICAL BONE LOSS IN VIVO. In ANNALS OF THE RHEUMATIC DISEASES (pp. 110-110). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:

Adam, Susanne, et al. "JAK-INHIBITORS TOFACITINIB AND BARICITINIB IMPROVE PATHOLOGICAL BONE LOSS IN VIVO." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 110-110.

BibTeX: Download